Ricevi le ultime notizie sulle azioni SeaStar Medical Holding con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ICU

Ultime notizie per

SeaStar Medical Holding

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding Corp

ICU Medical Inc

SeaStar Medical Holding Corporation - Warrant

Health Care

Press Releases

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

Earnings

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

Analyst Ratings

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

News

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Check-Cap

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

electroCore

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

Femasys

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Iridex

Lifeward

Milestone Scientific

Myomo

Neuraxis

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Nexalin Technology

PAVmed

Profusa

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

SINTX Technologies

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Tenon Medical

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Beyond Air

Maxim Group

Screenshot 2025-07-10 at 8.34.03 PM

Biotech

KERX

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern.

SeaStar Medical&#39;s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka

Screenshot 2025-06-26 at 7.23.46 PM

SeaStar&#39;s QUELIMMUNE Can Cut Pediatric Sepsis Deaths In Half

Screenshot 2025-06-26 at 7.15.22 PM

Interview

EXECUTIVE INTERVIEW: SeaStar CMO And Pediatric Specialist Talk About Promising Therapy To Treat Pediatric AKI

Screenshot 2025-05-28 at 5.34.56 PM

SeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market

Screenshot 2025-05-20 at 9.17.04 PM

Movers & Shakers

How SeaStar Medical Is Leveraging Its Breakthrough Medical Device Designation To Help Critically Ill Patients

Screenshot 2025-05-12 at 5.46.23 PM

How SeaStar Medical Joined Select Ranks Of Medical Device Innovators With Six FDA Breakthrough Device Designations

Screenshot 2025-05-08 at 5.53.49 PM

SeaStar&#39;s QUELIMMUNE Therapy For Pediatric AKI Adopted By Hospitals In Multiple States, Adult Treatment In Pipeline

Comments

SeaStar Medical Holding Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO